Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Harutyunyan L; Meliksetyan K; Oganesyan A; Oseyan H; Khachatryan H; Hakobyan Y

Accueil du journal

Indexé dans

Genamics JournalSeek
Infrastructure nationale des connaissances en Chine (CNKI)
CiteFactor
CINAHL complet
Scimago
Bibliothèque des revues électroniques
Répertoire d'indexation des revues de recherche (DRJI)
EMCare
OCLC - WorldCat
Commission des bourses universitaires
Fondation genevoise pour la formation et la recherche médicales
Pub européen
Google Scholar
SHERPA ROMÉO
Laboratoires secrets des moteurs de recherche

Partager cette page

Abstrait

Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability

Harutyunyan L, Meliksetyan K, Oganesyan A, Oseyan H, Khachatryan H and Hakobyan Y

Primary myelofibrosis (PMF) is a hematologic malignancy belonging to Ph negative myeloproliferative neoplasms (MPN), and it is commonly characterized by a higher risk of acute myeloid leukemia (AML) transformation. The aim of this case report is a demonstration of treatment with low dose cytarabine (LDAC) for a non-transformed newly diagnosed PMF patient with the inability of oral therapy and post-splenectomy complications.

Revue des sciences de la santé

Indexé dans

Partager cette page

Abstrait

Case Report: LDAC for the Treatment of Post-Splenectomy Newly Diagnosed PMF Patent with Oral Treatment Inability